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Purpose: To report the experiences at our institute of pars plana vitrectomy (PPV) in combination with intravitreal 
triamcinolone acetonide (IVTA) injection in patients with retained lens material after cataract surgery.
Methods: The medical records of patients who underwent PPV between January 2005 and December 2006 after 
complicated cataract surgery in which lens material was dropped into the vitreous cavity were reviewed retro-
spectively.
Results: Five eyes of five patients were treated by vitrectomy and removal of the dislocated lens material and were 
administered an adjuvant intravitreal injection of 4 mg triamcinolone acetonide at the end of surgery. IVTA 
administration induced a rapid improvement in vision within six weeks postoperatively. Final visual acuity was 
20/32 or better in all patients. Inflammatory cystoid macular edema (CME) that existed preoperatively was 
promptly improved after IVTA. Intraocular pressure increased transiently in one patient. No procedure-related 
complications were observed.
Conclusions: PPV with additional IVTA was successfully performed in five eyes with retained lens material and 
resulted in a marked resolution of vitreous inflammation, an improvement in CME and rapid visual recovery. The 
authors recommend that IVTA administration should be investigated more thoroughly as an adjunct during the 
management of retained lens material.
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The loss of a crystalline lens into the vitreous during cataract 
surgery is an uncommon but potentially serious complication. 
Dislocation of nuclear or cortical material into the vitreous 
can result in corneal edema, secondary glaucoma, vitritis, 
cystoid macular edema (CME), and retinal detachment, as 
well as reduced vision.
1
Although pars plana vitrectomy (PPV) is an established 
treatment modality for retained lens material, serious late 
complications have been reported after PPV, e.g., persistent 
CME, epimacular proliferation and choroidal detachment.
2-4 
Intravitreal triamcinolone (IVTA) was introduced for the less 
invasive treatment of retinal inflammatory and edematous 
conditions, and this method has become popular for the 
treatment of macular edema of various etiologies.
5,6
The authors suggest that IVTA combined with PPV might 
be helpful for reducing inflammation and macular edema in 
patients with retained lens material. We also thought that the 
concurrent use of IVTA and PPV is both convenient and 
efficient, and that it would reduce the need for postoperative 
steroid administration. The present study was undertaken to 
document our experience of the use of IVTA in combination 
with PPV in patients with retained lens material.
Materials and Methods
The medical records of patients treated at the retina depart-
ment of Inha University Hospital from January 2005 to December 
2006 who underwent PPV after complicated cataract surgery 
in which lens material was dropped into the vitreous cavity 
were retrospectively reviewed. Five eyes of five patients who 
received PPV and additional IVTA at the same time for the 
treatment of retained lens material were included in this 
study. Patients with coexisting macular disease (i.e., advanced 
age-related macular degeneration, diabetic retinopathy, retinal 
vein occlusion, and visually significant macular pucker) were 
excluded.
These five patients were treated by standard three-port 
PPV, lens fragment removal and adjuvant IVTA under retro-
bulbar anesthesia. All procedures were performed by the Korean J Ophthalmol Vol.23, No.1, 2009
14
same surgeon. Lens fragments were removed using an ultra-
sound fragmatome and/or a vitreous cutter, and then intraocular 
lenses (IOL) were properly implanted. Inspection of the 
retinal periphery with scleral depression and treatment of any 
peripheral retinal breaks were routinely performed at the 
conclusion of surgery. Sclerotomy sites were closed with 7-0 
polyglactin (Vicryl). IVTA was performed in the same 
surgical field immediately after the conclusion of vitrectomy. 
Triamcinolone acetonide was injected into the vitreous infero-
temporally (4 mg in 0.1 mL) where the infusion cannula was 
removed, using a 30-gauge needle. IVTA was used to resolve 
macular edema and inflammatory response. The procedure 
was concluded with the subconjunctival injection of anti-
biotics. No other systemic corticosteroid was subsequently 
administered.
During postoperative follow-up, topical antibiotics and 
steroid eyedrops (fluorometholone 0.1%) were administered 
for four to five weeks. All participants underwent slit-lamp 
examination, fundus examination, Goldmann applanation 
tonometry, and best-corrected visual acuity (BCVA) testing 
at each visit. Inflammatory activity was judged by the presence 
of cells in the anterior chamber or the vitreous cavity. Optical 
coherence tomography (OCT) (Stratus Zeiss Humphrey, San 
Leandro, CA, USA) was performed six months after IVTA 
combined with PPV.
Results
The five participants included by retrospective chart review 
had the following characteristics: (1) referral after complicated 
cataract surgery in which lens material had been dropped into 
the vitreous cavity; (2) over a one-week interval to PPV after 
complicated cataract surgery; (3) symptomatic vision loss 
from CME in the involved eye, which was diagnosed either 
before or during PPV; and (4) the presence of marked post-
operative inflammatory response in the involved eye that 
obscured retinal details.
Pretreatment characteristics and the results of PPV and 
IVTA are summarized in Table 1. Five participants between 
the ages of 58-79 years (mean±SD; 71.0±7.906) were followed 
for at least six months (range: six to eight months). Of these 
five patients with retained lens material, two patients had 
dense nuclei. Other preexisting eye conditions included 
diabetic mellitus and primary open-angle glaucoma. At the 
time of cataract surgery, three patients underwent anterior 
vitrectomy combined with phacoemulsification.
Visual acuities at the initial visits ranged from 20/200 to 
hand movement (HM). One patient had an intraocular pressure 
of greater than 25 mmHg at the time of referral. All patients 
showed mild to moderate corneal edema. However, no patient 
presented with a level of corneal edema that interfered with 
fundus visibility during vitrectomy. The average time between 
the complicated cataract operation and PPV was 15.0±5.701 
days.
Three patients already had an intraocular lens (IOL) in the 
sulcus at the time of referral, thus we reapplied it as it was. 
The IOL that had dislocated into the vitreous in one patient 
was retrieved at the time of PPV. In one eye left aphakic 
before PPV, the state of the capsule was assessed and a 
posterior chamber intraocular lens (PCIOL) was inserted into 
the sulcus because adequate capsular support was present. 
None of the eyes was left aphakic after our study.
An improvement in both inflammation and visual acuity 
was noted in all cases within one to two weeks after the 
procedure. By six weeks after treatment, visual acuity in the 
affected eyes had increased from HM to 20/50, from 20/200 
to 20/25, from counting fingers (CF) to 20/32, from CF to 
20/40, and from HM to 20/40. Final visual acuity at the last 
follow-up (mean±SD; 27.2±3.633 weeks) was 20/32 or better 
in all eyes (range: 20/32 to 20/25). Inflammatory CME that 
existed preoperatively in these patients quickly improved 
after IVTA. An OCT scan in one patient revealed a decrease 
in retinal edema at two weeks postoperatively and no recurrence 
at six months.
No procedure-related complications were observed in any 
patient. One patient experienced a transient postoperative ele-
vation in intraocular pressure of 32 mmHg that resolved 
quickly after instilling topical brimonidine. Late complications, 
such as persistent CME or retinal detachment, were not 
encountered.
Discussion
PPV with additional IVTA was successfully performed in 
five eyes with retained lens material and resulted in a marked 
resolution of vitreous inflammation, a prompt improvement 
in CME and rapid visual recovery. The effect of IVTA plus 
PPV was as we had hoped, and no extraordinary complica-
tions occurred.
There is some basis for recommending IVTA as safe 
adjunctive option for the treatment of retained lens material. 
First, the advantages of PPV plus IVTA in our patients were 
rapid and effective reduction in inflammation and quick 
improvement of vision. Though visual acuity in many patients 
with retained lens material might be improved spontaneously 
after removal of the lens material, prompt visual rehabilitation 
is preferable because both physicians and patients require 
rapid visual recovery in these complicated cases. The results 
of the present study suggest that IVTA provides an effective 
tool during the treatment of retained lens material because it 
shortens the duration of inflammation and quickly increases 
visual acuity.
Second, we found that IVTA during PPV benefits patients 
with CME, which is the main macular pathology underlying 
poor visual acuity in cases with retained lens material. It is 
generally accepted that complicated cataract surgery increases 
the risk of CME.
7 CME in cases of retained lens material 
appears to be related to increased levels of inflammatory 
mediators released by uveal tissues, and this is known to 
occur when the anterior hyaloid face is ruptured and/or when NR Kim, et al. PPV WITH IVTA FOR RETAINED LENS MATERIAL
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lens fragments are retained.
8 Moreover, surgical procedures 
in patients with an inflamed eye are associated with a higher 
incidence of CME.
9 Corticosteroids are administered during 
CME treatment to inhibit the biosynthetic pathways of ara-
chidonic acid and also to stabilize the blood–retinal barrier.
10 
We consider that adjuvant IVTA at the time of PPV in cases 
of retained lens material could have an additional benefit on 
CME recovery and on the prevention of persistent CME.
Third, combining IVTA injection and PPV is advantageous 
because it reduces effort and time. IVTA can be conveniently 
performed at the time of PPV, and this reduces the need for 
additional treatment after surgery by achieving a therapeutic 
concentration of intraocular steroids.
Fourth, combined IVTA/PPV was performed safely in our 
participants. The reported complications of IVTA include: 
secondary ocular hypertension, a medically uncontrollable 
high IOP, steroid-induced cataract, and rarely, endophthalmitis. 
In our patients, we were not concerned about cataract formation 
because crystalline lenses had already been removed. One 
patient experienced an IOP increase but stabilized in three 
days. In fact, IVTA shows a somewhat limited effect in vitrec-
tomized eyes because of a faster clearance of triamcinolone 
acetonide (TA) in the eye.
11 However, a faster clearance of 
TA was actually rather advantageous to our cases because it 
lowered the possibility of complications of IVTA.
We recognize that the present study is limited by its small 
sample size, non-homogeneous cases, lack of a control group, 
and relatively short follow-up. However, despite these limi-
tations, we found that additional IVTA during PPV in selected 
cases is safe and that it can promote visual rehabilitation. 
More detailed study is required to determine the role of 
additional IVTA during the management of patients with 
retained lens material.
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